N-CBZ-羟脯氨酸甲酯 | 64187-48-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 脯氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-CBZ-羟脯氨酸甲酯
• 中文别名: Z-羟脯氨酸甲酯；N-CBZ-反式-L-羟脯氨酸甲酯；N-Cbz-反式-L-羟脯氨酸甲酯
• 英文名称: methyl (2S,4R)-1-benzyloxycarbonyl-4-hydroxypyrrolidine-2-carboxylate
• 英文别名: 1-benzyl 2-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate；(2S,4R)-1-benzyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate；(2S,4R)-N1-(benzyloxycarbonyl)-4-hydroxyproline methyl ester；(2S,4R)-4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-benzyl ester 2-methyl ester；(2S,4R)-N-benzyloxycarbonyl-4-hydroxyproline methyl ester；Z-HYP-OMe；1-O-benzyl 2-O-methyl (2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate
• CAS: 64187-48-0
• 化学式: C₁₄H₁₇NO₅
• mdl: MFCD00055851
• 分子量: 279.293
• InChiKey: VVKAGQHUUDRPOI-NEPJUHHUSA-N

物化性质

• 沸点：
  422.8±45.0 °C(Predicted)
• 密度：
  1.313
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。
• 稳定性/保质期：
  在指定条件下稳定，远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• WGK Germany：
  3
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存放在密封容器内，并置于阴凉、干燥处。避免与氧化剂接触。应在-20°C下保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-Hyp-OMe
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-Hyp-OMe
CAS number: 64187-48-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H17NO5
Molecular weight: 279.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Z-Hyp-Me是一种生物化学试剂，可用于生物材料或有机化合物的研究，在生命科学领域中发挥重要作用。

反应信息

• 作为反应物：
  描述：

  N-CBZ-羟脯氨酸甲酯 在 N-甲基吗啉 、 咪唑 、 4-二甲氨基吡啶 、 锂硼氢 、 偶氮二甲酸二异丙酯 、 四丁基氟化铵 、 四丁基氯化铵 、 氢溴酸 、 palladium diacetate 、 sodium hydride 、 二异丁基氢化铝 、 碳酸氢钠 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 三苯基膦 、 三氟乙酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium hydroxide 、 对硝基苯甲酸 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 、 甲醇 、 二氯甲烷 、 水 为溶剂， 反应 119.0h， 生成 比瑞那帕
  参考文献：
  名称：

  Birinapant的工艺开发与合成：关键吲哚中间体的大规模制备和酸介导的二聚化

  摘要：

  Birinapant / TL32711（1）是细胞凋亡抑制剂（IAP）蛋白家族的新型二价拮抗剂，目前正在临床开发中，用于治疗癌症和乙型肝炎病毒（HBV）感染。在本报告中，我们对用于支持我们正在进行的临床研究的1种原料药的合成进行了详细说明。在此过程中的关键转换包括以酰基一个可扩展的，高产路线的吲哚的发展14以及吲哚两步二聚化/氧化19即得到biindole 21在良好的产率和纯度（70％产率，2步;通过HPLC分析，纯度＞ 95面积％。另外，部分脱氟为21在除去氢介导的苄氧羰基（Cbz）保护基之后观察到该反应，该保护基通过使用HBr / HOAc用于该转化而消除。使用可商购的氨基酸衍生物提供了相关杂质，证明其在后续步骤中难以清除。因此，限定用于这些试剂中的杂质规格是提供关键1种> 99面积％的化学纯度的药物物质。通过此过程，我们已经成功地以大于500克的规模多次制备了1种原料药，以支持我们的临床开发计划。

  DOI：

  10.1021/acs.oprd.5b00390
• 作为产物：
  描述：

  L-羟基脯氨酸 在 氯化亚砜 、 碳酸氢钠 作用下， 以 水 为溶剂， 生成 N-CBZ-羟脯氨酸甲酯
  参考文献：
  名称：

  Two prolines with a difference: contrasting stereoelectronic effects of 4R/S-aminoproline on triplex stability in collagen peptides [Pro(X)-Pro(Y)-Gly]nElectronic supplementary information (ESI) available: 1H NMR spectra and coupling constant analysis of 3 and 4; synthetic schemes for 3, 4, 5 and 6; FABMS of 3 and 4; MALDI-TOF MS of 5 and 6; HPLC of peptides 5 and 6. See http://www.rsc.org/suppdata/cc/b3/b308581c/

  摘要：

  在胶原肽[pro(X)-pro(Y)-Gly]n中，当4R/S-氨基脯氨酸位于X位置时，对三重螺旋稳定性表现出pH和立体化学依赖性效应。

  DOI：

  10.1039/b308581c

文献信息

• Substituted Imidazopyridines as HDM2 Inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20140179680A1

  公开（公告）日：2014-06-26

  The present invention provides substituted imidazopyridines as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same.

  本发明提供了如本文所述的取代咪唑吡啶或其药用可接受的盐或溶剂。代表性化合物可用作HDM2蛋白的抑制剂。还公开了包括上述化合物的药物组合物以及使用它们治疗癌症的潜在方法。
• PROCESS FOR PRODUCTION OF CIS-4-FLUORO-L-PROLINE DERIVATIVES
  申请人：Taisho Pharmaceutical Co. Ltd.

  公开号：EP1657237A1

  公开（公告）日：2006-05-17

  The present invention provides a safer method for production of a cis-4-fluoro-L-proline derivative under milder conditions and in good yield to give a product of high purity on an industrial scale at low cost. Namely, the present invention provides a method for producing a cis-4-fluoro-L-proline derivative, which comprises reacting a trans-4-hydroxy-L-proline derivative of the following Formula [I]: (wherein R1 represents a protecting group for an α-amino group, and R2 represents a protecting group for a carboxyl group) with N,N-diethyl-N-(1,1,2,3,3,3-hexafluoropropyl)amine in the presence of a hydrogen fluoride-scavenger.

  本发明提供了一种更安全的方法，用于在较温和的条件下且高产率地生产cis-4-氟-L-脯氨酸衍生物，以在工业规模下以低成本提供高纯度的产品。换句话说，本发明提供了一种生产cis-4-氟-L-脯氨酸衍生物的方法，包括将以下式[I]的trans-4-羟基-L-脯氨酸衍生物（其中R1代表α-氨基的保护基，R2代表羧基的保护基）与N,N-二乙基-N-(1,1,2,3,3,3-六氟丙基)胺在氢氟酸清除剂的存在下反应。
• SUBSTITUTED BENZOXAZOLES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160108027A1

  公开（公告）日：2016-04-21

  The invention relates to substituted benzoxazoles and to processes for their preparation and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders, preferably of thrombotic or thromboembolic disorders.

  本发明涉及取代苯并恶唑及其制备方法，以及它们用于制备治疗和/或预防疾病，特别是心血管疾病，尤其是血栓性或血栓性栓塞疾病的药物的应用。
• 取代的苯并噁唑
  申请人：拜耳制药股份公司

  公开号：CN105431428A

  公开（公告）日：2016-03-23

  本发明涉及式(I)的取代的苯并噁唑（其中R 1 表示下式的基团）和其制备方法以及它们用于制备如下目的的药物的用途：治疗和/或预防疾病，特别是心血管的病症，优选血栓形成的或血栓栓塞的病症。
• NOVEL BENZODIAZEPINE DERIVATIVES AND USES THEREOF
  申请人：IntoCell, Inc.

  公开号：US20190367488A1

  公开（公告）日：2019-12-05

  The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof.

  本公开提供了能够延长寿命的化合物和组合物，以及其使用方法。